Seroatlas · Human Serome Atlas

CYP2A13

Cytochrome P450 2A13

Also known as: CP2AD_HUMAN, CPAD, CYP2A

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q16696
Gene
CYP2A13
Ensembl
ENSG00000197838
Chromosome
19
Canonical length
494 aa
Protein class
Enzymes, Metabolic proteins, Predicted intracellular proteins
Secretome location
Intracellular and membrane

OverviewNCBI Gene

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. Although its endogenous substrate has not been determined, it is known to metabolize 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a major nitrosamine specific to tobacco. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

494 residues, UniProt reviewed canonical sequence.

>Q16696|CYP2A13
     1  MLASGLLLVT LLACLTVMVL MSVWRQRKSR GKLPPGPTPL PFIGNYLQLN TEQMYNSLMK
    61  ISERYGPVFT IHLGPRRVVV LCGHDAVKEA LVDQAEEFSG RGEQATFDWL FKGYGVAFSN
   121  GERAKQLRRF SIATLRGFGV GKRGIEERIQ EEAGFLIDAL RGTHGANIDP TFFLSRTVSN
   181  VISSIVFGDR FDYEDKEFLS LLRMMLGSFQ FTATSTGQLY EMFSSVMKHL PGPQQQAFKE
   241  LQGLEDFIAK KVEHNQRTLD PNSPRDFIDS FLIRMQEEEK NPNTEFYLKN LVMTTLNLFF
   301  AGTETVSTTL RYGFLLLMKH PEVEAKVHEE IDRVIGKNRQ PKFEDRAKMP YTEAVIHEIQ
   361  RFGDMLPMGL AHRVNKDTKF RDFFLPKGTE VFPMLGSVLR DPRFFSNPRD FNPQHFLDKK
   421  GQFKKSDAFV PFSIGKRYCF GEGLARMELF LFFTTIMQNF RFKSPQSPKD IDVSPKHVGF
   481  ATIPRNYTMS FLPR

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CYP2A13 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Other membrane
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.22
Highest tissue expression
1.9 nTPM

Expression across tissuesHPA

Tissue

  • liver: 1.9 nTPM
  • cervix: 0.1 nTPM
  • lung: 0.1 nTPM
  • testis: 0.1 nTPM
  • urinary bladder: 0.1 nTPM
  • vagina: 0.1 nTPM

Single-cell type

  • conjunctival goblet cells: 110 nCPM
  • respiratory secretory cells: 74 nCPM
  • respiratory deuterosomal cells: 22 nCPM
  • submucosal glandular cells: 9.1 nCPM
  • respiratory basal cells: 7.6 nCPM
  • early spermatids: 7.1 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • cerebral cortex: 0.3 nTPM
  • amygdala: 0.2 nTPM
  • basal ganglia: 0.2 nTPM
  • hippocampal formation: 0.2 nTPM
  • hypothalamus: 0.2 nTPM
  • medulla oblongata: 0.2 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.09
gnomAD pLI
0
gnomAD missense Z
-1.67
DepMap mean gene effect
-0.16
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CYP2A13 as an antibody target. Whether an autoantibody or antibody against CYP2A13 could matter depends on whether native CYP2A13 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CYP2A13 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label CYP2A13 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/CYP2A13. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...